343 related articles for article (PubMed ID: 28973645)
1. Alpha-synuclein induces the unfolded protein response in Parkinson's disease SNCA triplication iPSC-derived neurons.
Heman-Ackah SM; Manzano R; Hoozemans JJM; Scheper W; Flynn R; Haerty W; Cowley SA; Bassett AR; Wood MJA
Hum Mol Genet; 2017 Nov; 26(22):4441-4450. PubMed ID: 28973645
[TBL] [Abstract][Full Text] [Related]
2. Isogenic human SNCA gene dosage induced pluripotent stem cells to model Parkinson's disease.
Zafar F; Nallur Srinivasaraghavan V; Yang Chen M; Alejandra Morato Torres C; Schüle B
Stem Cell Res; 2022 Apr; 60():102733. PubMed ID: 35263701
[TBL] [Abstract][Full Text] [Related]
3. Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells.
Oliveira LM; Falomir-Lockhart LJ; Botelho MG; Lin KH; Wales P; Koch JC; Gerhardt E; Taschenberger H; Outeiro TF; Lingor P; Schüle B; Arndt-Jovin DJ; Jovin TM
Cell Death Dis; 2015 Nov; 6(11):e1994. PubMed ID: 26610207
[TBL] [Abstract][Full Text] [Related]
4. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.
Flierl A; Oliveira LM; Falomir-Lockhart LJ; Mak SK; Hesley J; Soldner F; Arndt-Jovin DJ; Jaenisch R; Langston JW; Jovin TM; Schüle B
PLoS One; 2014; 9(11):e112413. PubMed ID: 25390032
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus.
Devine MJ; Ryten M; Vodicka P; Thomson AJ; Burdon T; Houlden H; Cavaleri F; Nagano M; Drummond NJ; Taanman JW; Schapira AH; Gwinn K; Hardy J; Lewis PA; Kunath T
Nat Commun; 2011 Aug; 2():440. PubMed ID: 21863007
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
7. Modeling Parkinson's disease using induced pluripotent stem cells.
Byers B; Lee HL; Reijo Pera R
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
[TBL] [Abstract][Full Text] [Related]
8. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
[TBL] [Abstract][Full Text] [Related]
9. Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications.
Iannielli A; Luoni M; Giannelli SG; Ferese R; Ordazzo G; Fossati M; Raimondi A; Opazo F; Corti O; Prehn JHM; Gambardella S; Melki R; Broccoli V
Cell Death Dis; 2022 Oct; 13(10):881. PubMed ID: 36261424
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9-Edited SNCA Knockout Human Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons and Their Vulnerability to Neurotoxicity.
Inoue S; Nishimura K; Gima S; Nakano M; Takata K
Biol Pharm Bull; 2023; 46(3):517-522. PubMed ID: 36858582
[TBL] [Abstract][Full Text] [Related]
11. Generation of three clones (JUCGRMi002-A, B, C) of induced pluripotent stem cells from a Parkinson's disease patient with SNCA duplication.
Ishikawa KI; Shiga T; Yoshino H; Nishioka K; Hattori N; Akamatsu W
Stem Cell Res; 2024 Feb; 74():103296. PubMed ID: 38154385
[TBL] [Abstract][Full Text] [Related]
12. Using High-Content Screening to Generate Single-Cell Gene-Corrected Patient-Derived iPS Clones Reveals Excess Alpha-Synuclein with Familial Parkinson's Disease Point Mutation A30P.
Barbuti P; Antony P; Santos B; Massart F; Cruciani G; Dording C; Arias J; Schwamborn J; Krüger R
Cells; 2020 Sep; 9(9):. PubMed ID: 32927687
[TBL] [Abstract][Full Text] [Related]
13. Generation of gene-corrected iPSC line from Parkinson's disease patient iPSC line with alpha-SNCA A53T mutation.
Lee SY; Jeong S; Kim J; Chung SK
Stem Cell Res; 2018 Jul; 30():145-149. PubMed ID: 29906669
[TBL] [Abstract][Full Text] [Related]
14. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.
Byers B; Cord B; Nguyen HN; Schüle B; Fenno L; Lee PC; Deisseroth K; Langston JW; Pera RR; Palmer TD
PLoS One; 2011; 6(11):e26159. PubMed ID: 22110584
[TBL] [Abstract][Full Text] [Related]
15. Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson's disease.
Guhathakurta S; Kim J; Adams L; Basu S; Song MK; Adler E; Je G; Fiadeiro MB; Kim YS
EMBO Mol Med; 2021 Feb; 13(2):e12188. PubMed ID: 33428332
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD.
Kantor B; Tagliafierro L; Gu J; Zamora ME; Ilich E; Grenier C; Huang ZY; Murphy S; Chiba-Falek O
Mol Ther; 2018 Nov; 26(11):2638-2649. PubMed ID: 30266652
[TBL] [Abstract][Full Text] [Related]
17. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons.
Zambon F; Cherubini M; Fernandes HJR; Lang C; Ryan BJ; Volpato V; Bengoa-Vergniory N; Vingill S; Attar M; Booth HDE; Haenseler W; Vowles J; Bowden R; Webber C; Cowley SA; Wade-Martins R
Hum Mol Genet; 2019 Jun; 28(12):2001-2013. PubMed ID: 30753527
[TBL] [Abstract][Full Text] [Related]
18. Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations.
Singh Dolt K; Hammachi F; Kunath T
Brain Pathol; 2017 Jul; 27(4):545-551. PubMed ID: 28585381
[TBL] [Abstract][Full Text] [Related]
19. Generation of gene-corrected isogenic controls from Parkinson's disease patient iPSC lines carrying the pathogenic SNCA p.A53T variant.
Kozhushko N; Beilina A; Cookson MR
Stem Cell Res; 2023 Jun; 69():103125. PubMed ID: 37229975
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue.
Imaizumi Y; Okada Y; Akamatsu W; Koike M; Kuzumaki N; Hayakawa H; Nihira T; Kobayashi T; Ohyama M; Sato S; Takanashi M; Funayama M; Hirayama A; Soga T; Hishiki T; Suematsu M; Yagi T; Ito D; Kosakai A; Hayashi K; Shouji M; Nakanishi A; Suzuki N; Mizuno Y; Mizushima N; Amagai M; Uchiyama Y; Mochizuki H; Hattori N; Okano H
Mol Brain; 2012 Oct; 5():35. PubMed ID: 23039195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
